Skip to main content

Additional Articles by the Authors

Gary Branning, MBA
Kathryn Hayes, BA
Gary Branning, MBA; Heidi C. Waters, PhD; Christy R. Houle, PhD, MPH; Stacey L. Worthy, Esq; Betsy Fink, MBA, PMP; Katie Hayes
Cori Gray, PharmD; James T. Kenney, RPh, MBA
Outcomes-Based Contracts Gaining Traction: Innovative Therapies Will Require Innovative Payment Methods
Gary Branning, MBA
Gary Branning, MBA; Michael Lynch, CPA, MBA; Kathryn Hayes
Arijita Deb, PhD; Nilanjana Dwibedi, PhD; Traci LeMasters, PhD; Jo Ann Hornsby, MD; Wenhui Wei, PhD; Usha Sambamoorthi, PhD
Comorbidities in Rheumatoid Arthritis Present Clinical, Economic Challenges for All Stakeholders
Gary Branning, MBA
Gary Branning, MBA; Randy Ross, BA; Kathryn Hayes, BA
Dimitrios A. Pappas, MD; Robert A. Gerber, PharmD; Heather J. Litman, PhD; David Gruben, PhD; Jamie Geier, PhD; Winnie D. Hua, MS; Connie Chen, PharmD; Youfu Li, MD, MPH; Joel M. Kremer, MD; John S. Andrews, MD; Jeffrey A. Bourret, PharmD
Limited Guidelines and Treatment Success in the Current Standard of Care for Patients with Rheumatoid Arthritis Provide an Opportunity to Inform New Treatment Protocols
Gary Branning, MBA
Gary Branning, MBA, and Martha Vater
Gary Branning, MBA; Stacey L. Worthy, Esq; and Martha Vater
Jordan S. Orange, MD, PhD; Matt Johnson, BA; Barb Lennert, RN, BSN, MAOM; Katarzyna Shields, PharmD, MBA, BCOP, BCPS; Michael Eaddy, PharmD, PhD
A Useful Tool for Evaluating Disease Severity and Alternative Treatments Efficacy
Gary Branning, MBA
Joseph Lee, PhD; Ryan Pelkey, MS; Julieanna Gubitosa, BS; Michael F. Henrick, MBA; Michael L. Ganz, MS, PhD
Identifying the Most Clinically and Economically Effective Therapies for Rheumatoid Arthritis Remains a Challenge for Providers and Payers
Gary Branning, MBA
Page 1 of 2
Results 1 - 10 of 15